This website uses cookies
Read our Privacy policy and Terms of use for more information.
Oct 22, 2026
OpenAI acquires Orchestra Bio, GSK wins FDA approval for hepatitis B treatment, and EyePoint cuts staff after another Phase 3 setback.
Oct 20, 2026
Compounded GLP-1 ingredient factories face scrutiny, AstraZeneca backs insitro, and China’s biotech export proposal puts deal structures in focus.
Oct 15, 2026
Palantir’s CTO says some AI researchers are taking up smoking, betting on a cancer cure. Plus, BioNTech’s trial setback and Roche’s obesity deal.
Oct 13, 2026
Boston lab vacancy reaches 28.9%, BMS reports three Phase 3 readouts, and new Rasonque subgroup data put tumor response and survival in focus.
Oct 8, 2026
Biohub expands its AI biology effort to $1.8B as ArriVent misses a pivotal trial, Caribou halts CAR-T development, and Utah tests AI prescribing.
Oct 6, 2026
Vaxcyte reports pivotal vaccine results, Novartis licenses Abogen's mRNA program, and ARPA-H launches an effort to modernize clinical trials.
Oct 1, 2026
uniQure shares fall 37% on mixed Huntington’s data, AstraZeneca invests $2B in Summit, and Novo licenses a potential weekly GLP-1 pill.
Sep 29, 2026
Merck commits $400M to a preclinical KRAS drug, AbbVie wins a Parkinson’s approval, and Anthropic’s Claude finds an enzyme system with an unknown function.
Sep 24, 2026
Viking tests monthly GLP-1/GIP maintenance, Grail faces questions about cancer screening evidence, and nine pharma chairs warn Europe about investment.
